# A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.

> **NCT06546553** · PHASE1 · TERMINATED · sponsor: **Pfizer** · enrollment: 10 (actual)

## Conditions studied

- Neoplasms
- Non-small-cell Lung Cancer
- Squamous Cell Carcinoma of the Head and Neck
- Renal Cell Carcinoma
- Colorectal Carcinoma
- Ovarian Carcinoma

## Interventions

- **DRUG:** PF-07826390
- **BIOLOGICAL:** sasanlimab
- **OTHER:** SOC (anti-PD-1 + platinum -based chemo)

## Key facts

- **NCT ID:** NCT06546553
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-09-06
- **Primary completion:** 2025-10-03
- **Final completion:** 2025-10-03
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Study terminated as part of strategic considerations and not based on safety concerns.
- **Last updated:** 2026-02-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06546553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06546553, "A Study to Learn About How Different Amounts of the Study Medicine PF-07826390 Act in the Body of People With Cancer When Taken Alone or With Other Anti-cancer Medicines.". Retrieved via AI Analytics 2026-07-18 from https://api.ai-analytics.org/clinical/NCT06546553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*